Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

NCT05355168 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Toxicity, Drug

Interventions

DRUG: neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery

Sponsor

Anhui Provincial Hospital